Crossref
Charting a course for the expanded application of mRNA vaccine technology
Nucleic Acid Insights · 2024
DOI: 10.18609/nai.2024.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Insights, 2024. Verfasst von Myriam Mendila.
Abstract (Originalsprache)
A pioneer in the development of mRNA technology, CureVac has spent more than two decades in exploring its potential in both prophylactic and therapeutic vaccine settings. David McCall, Senior Editor, Nucleic Acid Insights, discusses the promise of next-generation approaches with Chief Development Officer, Myriam Mendila.
Zitieren
APA
Mendila, M. (2024). Charting a course for the expanded application of mRNA vaccine technology. Nucleic Acid Insights. https://doi.org/10.18609/nai.2024.001
Vancouver
Mendila M. Charting a course for the expanded application of mRNA vaccine technology. Nucleic Acid Insights. 2024. doi:10.18609/nai.2024.001
BibTeX
@article{Mendila2024,
author = {Mendila, Myriam},
title = {Charting a course for the expanded application of mRNA vaccine technology},
journal = {Nucleic Acid Insights},
year = {2024},
doi = {10.18609/nai.2024.001}
}
EUVIMED